| Executive Director CEO Commences - Appendix 3X | Nov 8, 2026 | Management or board change | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 27, 2026 | Quarterly report | ASX |
|---|
| Biotron Receives Additional $208,463 Tax Refund | Oct 22, 2026 | Results | ASX |
|---|
| Annual Report/Notice of AGM/Proxy Form | Oct 22, 2026 | Meeting notice | ASX |
|---|
| Director Appointment Michael Thurn & Appendix 3X | Oct 18, 2026 | Management or board change | ASX |
|---|
| Appointment of CEO and Executive Director | Oct 13, 2026 | Management or board change | ASX |
|---|
| Resignation of Managing Director and Appendix 3Z | Sep 13, 2026 | Management or board change | ASX |
|---|
| Change of Share Registry | Sep 3, 2026 | Other filings | ASX |
|---|
| Investor Presentation | Sep 2, 2026 | Other filings | ASX |
|---|
| Appendix 4G | Aug 26, 2026 | Other filings | ASX |
|---|
| Corporate Governance Statement | Aug 26, 2026 | Annual report | ASX |
|---|
| Full Year Statutory Accounts and Appendix 4E | Aug 26, 2026 | Annual report | ASX |
|---|
| Change in substantial holding | Aug 17, 2026 | Ownership change notice | ASX |
|---|
| HBV Treatment to Progress Towards Human Trials | Aug 16, 2026 | Other filings | ASX |
|---|
| Sedarex First Milestone Met | Jul 12, 2026 | Other filings | ASX |
|---|
| $525K R&D Rebate Received | Jun 3, 2026 | Results | ASX |
|---|
| Hepatitis B Virus Program Update | Mar 17, 2026 | Other filings | ASX |
|---|
| Half Yearly Report and Accounts | Feb 26, 2026 | Interim report | ASX |
|---|
| Successful Issue of the Entitlement Offer Shortfall | Jan 29, 2026 | Financing | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jan 28, 2026 | Quarterly report | ASX |
|---|
| Security Class Reinstatement to Quotation - BITO | Dec 21, 2025 | Trading halt or suspension | ASX |
|---|
| Rights Issue Close | Dec 19, 2025 | Financing | ASX |
|---|
| Security Class Suspension from Quotation - BITO | Dec 14, 2025 | Trading halt or suspension | ASX |
|---|
| Non-Renounceable rights Issue Prospectus | Nov 18, 2025 | Offer document | ASX |
|---|
| Acquisition of Sedarex Limited and $2.5m capital raising | Oct 15, 2025 | Acquisition or disposal | ASX |
|---|
| Trading Halt | Oct 12, 2025 | Trading halt or suspension | ASX |
|---|
| Pause in Trading | Oct 12, 2025 | Trading halt or suspension | ASX |
|---|
| Full Year Statutory Accounts and Appendix 4E | Aug 27, 2025 | Annual report | ASX |
|---|
| Rights Issue Closed | Apr 7, 2025 | Financing | ASX |
|---|
| Replacement Prospectus | Mar 12, 2025 | Offer document | ASX |
|---|
| Response to ASX Query Letter | Mar 12, 2025 | Explanation request | ASX |
|---|
| Supplementary Prospectus | Mar 4, 2025 | Offer document | ASX |
|---|
| Response to ASX Aware Query | Mar 3, 2025 | Explanation request | ASX |
|---|
| Prospectus | Mar 2, 2025 | Offer document | ASX |
|---|
| Renounceable Rights Issue | Feb 27, 2025 | Financing | ASX |
|---|
| Updated Appendix 4C | Feb 3, 2025 | Quarterly report | ASX |
|---|
| Agreement with C14 Consulting Group | Nov 26, 2024 | Other filings | ASX |
|---|
| $1.8M R&D Rebate Received | Oct 13, 2024 | Other filings | ASX |
|---|
| BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL | Sep 5, 2024 | Other filings | ASX |
|---|
| BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives | Jun 19, 2024 | Other filings | ASX |
|---|
| POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV | Apr 4, 2024 | Other filings | ASX |
|---|
| Response to ASX Price Query | Mar 26, 2024 | Explanation request | ASX |
|---|
| COMPLETION OF PHASE 2 COVID CLINICAL TRIAL | Aug 16, 2023 | Other filings | ASX |
|---|
| Second Site Approved for Phase 2 Covid-19 Trial | May 12, 2023 | Other filings | ASX |
|---|
| Commencement Phase 2 Covid-19 Clinical Trial | May 3, 2023 | Other filings | ASX |
|---|
| Completion of Phase 2 HIV-1 Clinical Trials | Mar 8, 2023 | Other filings | ASX |
|---|
| International Presentation of BIT225 COVID-19 Data | Feb 20, 2023 | Other filings | ASX |
|---|
| $1.43M R&D rebate received | Nov 18, 2022 | Other filings | ASX |
|---|
| Commencement of Rights Trading - BITRC | Oct 31, 2022 | Other filings | ASX |
|---|
| Renounceable Issue | Oct 26, 2022 | Other filings | ASX |
|---|
| Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited | Oct 3, 2022 | Other filings | ASX |
|---|
| Bit225 Covid-19 Human Study Commenced | Sep 13, 2022 | Other filings | ASX |
|---|
| BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited | Aug 23, 2022 | Other filings | ASX |
|---|
| POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM | May 30, 2022 | Guidance | ASX |
|---|
| BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS | May 2, 2022 | Other filings | ASX |
|---|
| Quarterly Cash Flow Report Appendix 4C | Apr 26, 2022 | Quarterly report | ASX |
|---|
| Quarterly Activities Report | Apr 26, 2022 | Quarterly report | ASX |
|---|
| $1.56M R&D Rebate Received | Apr 5, 2022 | Other filings | ASX |
|---|
| BIT225 Effectiveness Against COVID-19 in Animals | Mar 17, 2022 | Other filings | ASX |
|---|
| Quarterly Appendix 4C Cash Flow Report | Jan 27, 2022 | Quarterly report | ASX |
|---|
| BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS | Nov 24, 2021 | Other filings | ASX |
|---|
| COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS | Nov 1, 2021 | Other filings | ASX |
|---|
| Quarterly Cash Flow Report | Oct 27, 2021 | Quarterly report | ASX |
|---|
| Full Year Statutory Accounts and Preliminary Final Report | Aug 27, 2021 | Annual report | ASX |
|---|
| $1.4M R&D Tax Rebate | Apr 28, 2021 | Other filings | ASX |
|---|
| Appendix 4C - quarterly | Apr 28, 2021 | Quarterly report | ASX |
|---|
| Quarterly Cashflow Report | Jan 28, 2021 | Quarterly report | ASX |
|---|
| Biotron Compounds Show Activity Against SARS-CoV-2 Virus | Sep 6, 2020 | Other filings | ASX |
|---|
| Full Year Statutory Accounts | Aug 27, 2020 | Annual report | ASX |
|---|
| BIT225 Reverses HIV-Induced Immune Evasion | Jul 6, 2020 | Other filings | ASX |
|---|
| R&D Tax Refund Received | Mar 18, 2020 | Other filings | ASX |
|---|
| BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONS | Mar 11, 2020 | Other filings | ASX |
|---|
| Biotron to Test its Compounds Against Coronavirus | Feb 5, 2020 | Other filings | ASX |
|---|
| Biotron Secures $5.1 Million Underwriting Agreement | Nov 8, 2019 | Other filings | ASX |
|---|
| Presentation to Investors | Oct 31, 2019 | Other filings | ASX |
|---|
| Appointment of International Advisory Board for BIT225 | Oct 1, 2019 | Other filings | ASX |
|---|
| Presentation at BIO 2019 | Jun 7, 2019 | Other filings | ASX |
|---|
| PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATA | Nov 28, 2018 | Other filings | ASX |
|---|
| Response to ASX aware letter | Oct 30, 2018 | Explanation request | ASX |
|---|
| Biotron Secures $4.7 Million Underwriting Agreement | Oct 16, 2018 | Other filings | ASX |
|---|
| $1.07 million R&D Tax Incentive Received | Oct 14, 2018 | Other filings | ASX |
|---|
| Significant Immunological Outcomes in BIT225 HIV-1 Trial | Sep 28, 2018 | Other filings | ASX |
|---|
| Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial | Aug 7, 2018 | Other filings | ASX |
|---|
| Response to ASX Appendix 4C Query | May 10, 2018 | Explanation request | ASX |
|---|
| Biotron Compounds Demonstrate Activity Against HBV | Nov 15, 2017 | Other filings | ASX |
|---|
| $1.6 Million R&D Tax Incentive Received | Nov 1, 2017 | Other filings | ASX |
|---|
| BIT225 Phase 2 HIV-1 Clinical Trial Update | Jun 15, 2017 | Other filings | ASX |
|---|
| $1.6 Million R&D Tax Rebate Received | Feb 12, 2017 | Other filings | ASX |
|---|
| BIT225 Accelerates HIV-1 Virus Reduction | Feb 6, 2017 | Other filings | ASX |
|---|
| Zika Virus Program Update | Aug 22, 2016 | Other filings | ASX |
|---|
| Biotron compounds demonstrate activity against Zika virus | May 23, 2016 | Other filings | ASX |
|---|
| $1.5 Million R&D Tax Rebate | Apr 20, 2016 | Other filings | ASX |
|---|
| Trading halt | Mar 30, 2016 | Trading halt or suspension | ASX |
|---|
| Phase 2 Hepatitis C Trial Success | Mar 17, 2016 | Other filings | ASX |
|---|
| BIT225 MAY HAVE A BROADER ROLE IN LIMITING HIV-1 INFECTION | Feb 18, 2016 | Other filings | ASX |
|---|
| BIOTRON COMPOUNDS TESTED FOR ACTIVITY AGAINST ZIKA VIRUS | Feb 16, 2016 | Other filings | ASX |
|---|
| INTERIM HCV GENOTYPE 3 DATA FROM BIT225-008 STUDY | Feb 11, 2016 | Other filings | ASX |
|---|
| Annual Report to Shareholders | Feb 10, 2016 | Annual report | ASX |
|---|